Condition: Pancreatic Ductal Adenocarcinoma (PDAC) · Sponsor: ProDa BioTech, LLC
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel (G-nP) and atezolizumab in previously untreated subjects with metastatic pancreatic ductal adenocarcinoma (PDAC)
This description comes directly from the study's public registry record.
Damon R Michaels · 615-614-1185 · damon.michaels@medelis.com
Zhi-Ren Lui · zliu8@gsu.edu
Always discuss trial participation with your own doctor first.
| O'Neal Comprehensive Cancer Center, University of Alabama | Birmingham, Alabama, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06182072